Inflammatory bowel disease by Lee, Shona J. & Maizels, Rick M.
Evolution, Medicine, and Public Health [2014] p. 95 doi:10.1093/emph/eou017
Inflammatory Bowel Disease
Shona J. Lee1 and Rick M. Maizels2
1Centre for African Studies and 2Institute of Immunology and Infection Research, University of Edinburgh
Inflammatory bowel disease
Inflammatory bowel disease (IBD) is an im-
munological disorder, encompassing
Crohn’s disease and ulcerative colitis,
which are characterized by chronic intes-
tinal inflammation targeted at harmless
commensal bacteria and food antigens.
Although the aetiology of IBD remains un-
clear, environmental factors in susceptible
individuals appear to trigger immunolo-
gical responses that inflame and damage
tissues of the digestive tract. Prevalence of
IBDis markedly higher in industrializedand
affluent countries [1] (see Fig. 1). Evidence
of a major underlying role for genetic pre-
disposition to IBD raises the likelihood that
the origins of disease and the susceptibility
of the current human ‘immunome’ is the
evolutionary consequence of marked and
prolonged genetic selective pressure
exerted by infectious pathogens [3].
Evolutionary perspectives
The Hygiene Hypothesis suggests that
increasing allergic and autoimmune dis-
eases are related to improved hygiene, e.g.
the absence of helminth infections in more
developed countries [1]. Notably, allergic
diseases are less common where parasites
are rife, while the elimination of helminths
can increase the atopic response to aller-
gens. Our human ancestors would have
been exposed to such infections causing,
over evolutionary time, the human immune
system to be optimally calibrated for their
presence [3].
In helminth-free settings, our immune
system may be maladapted and, where free
of the dampening effect of helminths, may
over-react to harmless antigens. Multiple
studies have revealed that helminths sup-
press a broad range of inflammatory
responses [4], which may explain why ex-
posure to helminths such as Trichuris suis
(whipworm) has been reported to be well
tolerated by patients and improve IBD with-
out any overt side-effects in an open label
trial [5, 6]. These therapies are now being
evaluated in double-blind clinical trials.
Future clinical implications
As the precise aetiology of IBD is unknown,
no curative treatment is currently available
[2]. If positive results from pilot trials are
confirmed in larger efficacy trials, then it is
feasible thathelminths,applied inacontrol-
lable clinical setting, could relieve inflam-
matory disease. The immunoregulatory
effects of microbial exposure have moved
beyond hypothesis, with focus now turning
to their specific mechanisms [7], and a
greater understanding of the immunolo-
gical effects of helminths. Ultimately, this
field of research may lead to therapeutic
treatments for patients suffering from
inflammatory, autoimmune or allergic dis-
eases [8].
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Figure 1. Global incidence of IBD. Reprinted with permission from Elsevier [2].
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